CSL Vifor, Travere support KDIGO 2025 IgA Nephropathy clinical practice guidelines.

CSL Vifor and Travere Therapeutics support the updated clinical practice guidelines for IgA Nephropathy treatment. The guidelines define diagnostic criteria, treatment goals, and approaches, aiming to improve outcomes for patients and clinicians. The 2025 update sets remission of proteinuria and slowing eGFR decline as key goals, with treatment approaches aimed at achieving these objectives.

September 12, 2025 - CSL Vifor and Travere Therapeutics have expressed support for the recent update to the clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), published by Kidney Disease: Improving Global Outcomes (KDIGO) in 2025. The updated guidelines aim to provide a comprehensive framework for healthcare professionals to diagnose, treat, and manage IgAN and Immunoglobulin A vasculitis.

The 2025 update to the KDIGO guidelines defines diagnostic criteria, treatment goals, and approaches, focusing on improving long-term kidney outcomes for patients with IgAN. Key treatment goals include remission of proteinuria (defined as 0.5 g/day, ideally 0.3 g/day) and slowing the decline in estimated glomerular filtration rate (eGFR). The guidelines recommend a treatment approach that simultaneously targets IgAN-induced nephron loss and IgA formation.

FILSPARI® (sparsentan), the only Dual Endothelin Angiotensin Receptor Antagonist (DEARA), is highlighted as an appropriate first-line treatment for managing the responses of IgAN-induced nephron loss. The guidelines note that FILSPARI has proven efficacy compared to optimized RASi in clinical trials, with more patients enrolled in the PROTECT study than in all prior RASi trials combined CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy^[1].

The PROTECT study, a global, randomized, multicenter, double-blind, parallel-arm, active-controlled clinical trial, evaluated the safety and efficacy of FILSPARI (400 mg) compared to irbesartan (300 mg) in 404 patients with IgAN and persistent proteinuria despite receiving at least 50% of the maximum label dose and maximally tolerated ACE or ARB therapy. The trial met its primary endpoint, demonstrating a mean reduction in proteinuria from baseline of 49.8% in the FILSPARI group compared to 15.1% in the irbesartan group (p0.0001) CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy^[1].

The inclusion of FILSPARI in the updated KDIGO guidelines reflects its benefit-risk profile and reinforces its role in helping eligible patients reduce proteinuria and slow kidney function loss while being generally well-tolerated CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy^[1].

CSL Vifor and Travere Therapeutics have expressed optimism about the updated guidelines, highlighting the importance of clear, evidence-based guidance for clinicians treating this rare disease. The updated guidelines mark an important milestone for the IgA nephropathy community, reflecting advances in disease understanding and more sophisticated risk assessment and therapies CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy^[1].